We have previously shown that delivery of GMME1 via a gene-enhanced cellular platform to mice ill with EAE or arthritis, led to immune suppression and clinical remission and we here found that the same platform could serve to treat mice implanted with CCR2+ EG7 lymphoma. This evidence concerns the gene CCR2 and arthritic joint disease.